Aging-targeted pharma is moving from supplement claims toward indication-led trials, combination logic, and prevention endpoints.
Sources: [1]Reference 1TAME and geroscience trialsBarzilai et al., Cell Metabolism, 2016Use for the regulatory and trial-design logic behind metformin as a geroscience prototype.[2]Reference 2Surrogate endpoint standardsU.S. FDA surrogate endpoint resourcesUse for distinguishing biomarkers from accepted clinical benefit endpoints.
Key facts
- Portal
- Future Pharma
- Stage
- Mixed clinical maturity
- Evidence
- Early human
- Reversible
- Context dependent
- Reviewed
- Jun 2026
- Read time
- 7 min
Contents
Page status
Needs live pipeline table · Needs stronger regulatory endpoint citations
Key takeaways
- Most products will enter through specific diseases, not aging as a broad claim.
- Combination strategies may matter because aging mechanisms reinforce one another.
- Regulatory endpoints and payer logic are as important as biological plausibility.
Pipeline logic
The longevity pipeline includes senescence drugs, metabolic modulators, immune rejuvenation, mitochondrial interventions, proteostasisTermProteostasisThe maintenance of a healthy set of properly folded proteins; its loss is a hallmark of aging.In glossary → tools, and regenerative signals.
Aging is not yet a simple drug indication in most systems, so companies often target diseases where aging biology is a major driver.
Evidence problem
The ideal trial would show that an intervention delays multiple diseases or preserves function. That is expensive and slow.
Intermediate biomarkers can accelerate development, but only if they predict outcomes that patients and regulators care about.
Watchlist
Signals that would move this entry along the evidence scale.
Key terms
References
- TAME and geroscience trials. Barzilai et al., Cell Metabolism, 2016 Use for the regulatory and trial-design logic behind metformin as a geroscience prototype.
- Surrogate endpoint standards. U.S. FDA surrogate endpoint resources Use for distinguishing biomarkers from accepted clinical benefit endpoints.
Cite this page
Future Human Atlas. “Longevity Pharma Pipeline.” Last reviewed Jun 2026. https://futurehumanwiki.com/articles/longevity-pharma-pipeline